📊 BJDX Key Takeaways
Is Bluejay Diagnostics, Inc. (BJDX) a Good Investment?
Bluejay Diagnostics is an early-stage medical device company with minimal revenue ($249K) and severe burn rate (-$1.6M operating cash flow), limiting cash runway to approximately 2-3 years. Despite impressive 168% revenue growth and 19.6% gross margins, operating losses of -$1.9M on negligible sales and negative cash flow demonstrate the company cannot sustain operations without significant capital raise or rapid scaling.
Bluejay Diagnostics shows early-stage revenue growth, but the absolute revenue base remains extremely small relative to its operating cost structure, resulting in deeply negative operating and net margins. The balance sheet is currently supported by solid cash and no meaningful debt, but the business is consuming cash at a rate that is far too high for its present scale. Unless revenue ramps materially and losses narrow quickly, the current fundamentals indicate weak business quality and meaningful financing risk over time.
Bluejay Diagnostics, Inc. Key Strengths (BJDX)
- Strong revenue growth momentum (168% YoY)
- Healthy gross margin (19.6%) indicates viable product economics
- Adequate liquidity (2.81x current ratio, $3.7M cash) provides near-term runway
- Strong liquidity position with $5.16M in cash, a 4.88x current ratio, and no long-term debt
- Revenue grew 167.8% year over year, indicating some commercial traction from a low base
- Positive gross profit and positive equity of $5.98M provide near-term balance sheet support
BJDX Stock Risks: Bluejay Diagnostics, Inc. Investment Risks
- Critical cash burn: -$1.6M operating cash flow on $249K revenue; 3-year runway at current burn
- Extreme operating leverage problem: -$1.95M operating loss on minimal revenue signals massive cost structure relative to scale
- No clear path to profitability with negative FCF despite revenue growth; operating expenses consuming 8x quarterly revenue
- Extremely weak profitability, with operating margin of -2791.9% and net margin of -2750.0%
- Heavy cash burn, including -$6.05M operating cash flow and -$6.23M free cash flow, threatens sustainability
- Revenue remains far too small at $249.04K to absorb operating expenses, raising execution and dilution risk
Key Metrics to Watch
- Quarterly revenue absolute levels and growth sustainability (current $249K base too small)
- Operating cash flow trend and monthly burn rate in relation to cash balance
- Gross margin maintenance as revenue scales and whether OpEx can be controlled
- Quarterly revenue growth relative to operating expense growth
- Cash runway measured by operating cash burn versus cash balance
Bluejay Diagnostics, Inc. (BJDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.81x current ratio provides a solid financial cushion.
BJDX Profit Margin, ROE & Profitability Analysis
BJDX vs Healthcare Sector: How Bluejay Diagnostics, Inc. Compares
How Bluejay Diagnostics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bluejay Diagnostics, Inc. Stock Overvalued? BJDX Valuation Analysis 2026
Based on fundamental analysis, Bluejay Diagnostics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bluejay Diagnostics, Inc. Balance Sheet: BJDX Debt, Cash & Liquidity
BJDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bluejay Diagnostics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-456.75 indicates the company is currently unprofitable.
BJDX Revenue Growth, EPS Growth & YoY Performance
BJDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $249.0K | -$1.9M | $-2.08 |
| Q2 2023 | $249.0K | -$1.9M | $-2.00 |
| Q3 2022 | $249.0K | -$194.2K | $-0.11 |
| Q2 2022 | $249.0K | -$194.2K | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bluejay Diagnostics, Inc. Dividends, Buybacks & Capital Allocation
BJDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bluejay Diagnostics, Inc. (CIK: 0001704287)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BJDX
What is the AI rating for BJDX?
Bluejay Diagnostics, Inc. (BJDX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BJDX's key strengths?
Claude: Strong revenue growth momentum (168% YoY). Healthy gross margin (19.6%) indicates viable product economics. ChatGPT: Strong liquidity position with $5.16M in cash, a 4.88x current ratio, and no long-term debt. Revenue grew 167.8% year over year, indicating some commercial traction from a low base.
What are the risks of investing in BJDX?
Claude: Critical cash burn: -$1.6M operating cash flow on $249K revenue; 3-year runway at current burn. Extreme operating leverage problem: -$1.95M operating loss on minimal revenue signals massive cost structure relative to scale. ChatGPT: Extremely weak profitability, with operating margin of -2791.9% and net margin of -2750.0%. Heavy cash burn, including -$6.05M operating cash flow and -$6.23M free cash flow, threatens sustainability.
What is BJDX's revenue and growth?
Bluejay Diagnostics, Inc. reported revenue of $249.0K.
Does BJDX pay dividends?
Bluejay Diagnostics, Inc. does not currently pay dividends.
Where can I find BJDX SEC filings?
Official SEC filings for Bluejay Diagnostics, Inc. (CIK: 0001704287) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BJDX's EPS?
Bluejay Diagnostics, Inc. has a diluted EPS of $-1.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BJDX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Bluejay Diagnostics, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BJDX stock overvalued or undervalued?
Valuation metrics for BJDX: ROE of -45.9% (sector avg: 15%), net margin of -770.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BJDX's AI grade for 2026?
Our dual AI analysis gives Bluejay Diagnostics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BJDX's free cash flow?
Bluejay Diagnostics, Inc.'s operating cash flow is $-1.6M, with capital expenditures of $19.0K. FCF margin is -645.8%.
How does BJDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -770.7% (avg: 12%), ROE -45.9% (avg: 15%), current ratio 2.81 (avg: 2).